Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by 18 F-FLT PET scanning

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 110-115

  Woolthuis, C ^a   Agool, A ^a   Olthof, S ^a   Slart, R H J A ^a   Huls, G ^a   Smid, W M ^a   Schuringa, J J ^a   Vellenga, E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

18F FLT PET; auto SCT; BM defects; cell cycle; progenitor subsets

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; RADIOPHARMACEUTICAL AGENT; TRIFLURIDINE F 18; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD34 SELECTION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLONOGENESIS; COLONY FORMING UNIT GM; COMMON MYELOID PROGENITOR; CONTROLLED STUDY; DRUG MEGADOSE; DRUG UPTAKE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD34; BONE MARROW; CELL CYCLE; COLONY-FORMING UNITS ASSAY; DIDEOXYNUCLEOSIDES; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MIDDLE AGED; MOLECULAR IMAGING; MYELOID PROGENITOR CELLS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, AUTOLOGOUS; WHOLE BODY IMAGING;

EID: 78651351908     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.75     Document Type: Article

References (20)

1. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124-127.
2. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood 2008; 111: 537-543.
3. Noach EJ, Ausema A, van Os R, Akkerman I, Koopal S, Weersing E et al. Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice. Exp Hematol 2003; 31: 528-534.
4. Domenech J, Linassier C, Gihana E, Dayan A, Truglio D, Bout M et al. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood 1995; 85: 3320-3327.
5. Widmann T, Kneer H, König J, Herrmann M, Pfreundschuh M. Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol 2008; 36: 104-110.
6. Thornley I, Sutherland DR, Nayar R, Sung L, Freedman MH, Messner HA. Replicative stress after allogeneic bone marrow transplantation: Changes in cycling of CD34+CD90+ and CD34+CD90- hematopoietic progenitors. Blood 2001; 97: 1876-1878.
7. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 2002; 99: 11872-11877.
8. Edvardsson L, Dykes J, Olofsson T. Isolation and characterization of human myeloid progenitor populations-TpoR as discriminator between common myeloid and megakaryocyte/ erythroid progenitors. Exp Hematol 2006; 34: 599-609.
9. Olthof SG, Fatrai S, Drayer AL, Tyl MR, Vellenga E, Schuringa JJ. Downregulation of STAT5 in CD34+ cells promotes megakaryocytic development while activation of STAT5 drives erythropoiesis. Stem Cells 2008; 26: 1732-1742.
10. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-1336.
11. Agool A, Schot BW, Jager PL, Vellenga E. 18F-FLT PET in hematologic disorders: A novel technique to analyze the bone marrow compartment. J Nucl Med 2006; 47: 1592-1598.
12. Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007; 110: 2880-2888.
13. Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 2005; 23: 6699-6711.
14. Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA 2005; 102: 9194-9199.
15. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 2007; 447: 725-729.
16. Ju Z, Jiang H, Jaworski M, Rathinam C, Gompf A, Klein C et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med 2007; 13: 742-747.
17. Kimura T, Asada R, Wang J, Kimura T, Morioka M, Matsui K et al. Identification of long-term repopulating potential of human cord blood-derived CD34-flt3- severe combined immunodeficiency- repopulating cells by intra-bone marrow injection. Stem Cells 2007; 25: 1348-1355.
18. Li Q, Hisha H, Yasumizu R, Fan TX, Yang GX, Li Q et al. Analyses of very early hemopoietic regeneration after bone marrow transplantation: Comparison of intravenous and intrabone marrow routes. Stem Cells 2007; 25: 1186-1194.
19. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G et al. Direct intrabone transplant of unrelated cordblood cells in acute leukaemia: A phase I/II study. Lancet Oncol 2008; 9: 831-839.
20. Castello S, Podestà M, Menditto VG, Ibatici A, Pitto A, Figari O et al. Intra-bone marrow injection of bone marrow and cord blood cells: An alternative way of transplantation associated with a higher seeding efficiency. Exp Hematol 2004; 32: 782-787.